Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration

Abstract

Abstract Mitochondrial membrane protein-associated neurodegeneration (MPAN) is an ultraorphan neurogenetic disease from the group of Neurodegeneration with Brain Iron Accumulation (NBIA) disorders. Here we report cross-sectional and longitudinal data to define the phenotype, to assess disease progression, and to estimate sample sizes for clinical trials. We enrolled patients with genetically confirmed MPAN from the Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) registry and cohort study, and from additional sites. Linear mixed-effect modelling (LMEM) was used to calculate annual progression rates for Unified Parkinson's Disease Rating Scale (UPDRS), Barry-Albright Dystonia (BAD) Scale, Schwab and England Activities of Daily Living (SE-ADL) scale, and the Pediatric Quality of Life Inventory (PedsQL). We investigated 85 MPAN patients cross-sectionally, with functional outcome data collected in 45. Median age at onset was 9 years and the median diagnostic delay was 5 years. The most common findings were gait disturbance (99%), pyramidal involvement (95%), dysarthria (90%), vision disturbances (82%), with all but dysarthria presenting early in the disease course. After 16 years into disease, 50% of patients were wheelchair dependent. LMEM showed an annual progression rate of 4.5 points in total UPDRS. The total BAD scale showed no significant progression over time. The SE-ADL scale, the patient- reported and the parent-reported PedsQL showed a decline of 3.9%, 2.14 and 2.05 points respectively. No patient subpopulations were identified based on longitudinal trajectories. Interpretation: Our cross-sectional results define order of onset and frequency of symptoms in MPAN, which will inform the diagnostic process, help shorten the diagnostic delay, and aid in counselling patients, parents, and caregivers. Our longitudinal findings define the natural history of MPAN, reveal the most responsive outcomes, and highlight the need for an MPAN-specific rating approach. Our sample size estimations inform the design of upcoming clinical trials.